Secondary outcome measure | Patient subgroup | Baseline | 3 months | 6 months |
---|---|---|---|---|
Pain visual analogic scale | Hyalubrix® group | 6.4 ± 1.94 | 4.3 ± 2.58a | 4.5 ± 1.96a |
Mepivacaine group | 6.0 ± 1.34 | 4.5 ± 2.63 | 5.0 ± 2.41 | |
NSAID consumption | Hyalubrix® group | 8.5 ± 3.6 | 2.1 ± 0.4 | 1.5 ± 0.5 |
Mepivacaine group | 6.9 ± 2.2 | 5.5 ± 3.0 | 2.3 ± 1.0 | |
Global physician assessment | Hyalubrix® group | 5.5 ± 1.58 | 4.4 ± 1.49 | 4.0 ± 1.51 |
Mepivacaine group | 5.1 ± 1.41 | 4.5 ± 1.61 | 4.3 ± 1.61 | |
Global patient assessment | Hyalubrix® group | 6.1 ± 2.07 | 4.5 ± 2.31 | 4.0 ± 2.06 |
Mepivacaine group | 5.7 ± 1.68 | 4.7 ± 2.33 | 4.9 ± 2.01 |